Ricerc@Sapienza

Aim: In this study, we compared perioperative and oncologic outcomes of patients treated with either open or robot-assisted radical cystectomy and intracorporeal neobladder at a tertiary care center. Methods: The institutional prospective bladder cancer database was queried for “cystectomy with curative intent” and “neobladder”.

Background: to Optimize Outcomes Reporting After Robot-Assisted Radical Cystectomy (Rarc) With Intracorporeal Orthotopic Neobladder (Ion), We Propose a Novel Trifecta, Aimed to Overcome The Available Pentafectas That Neglect FuncTional Outcomes. Methods: a Retrospective Analysis of Prospectively Maintained Rarc-Ion Dataset Was Performed. Baseline DemoGraphic, Clinical, Pathologic, Perioperative and Follow-Up Data Were Collected. Trifecta Was Defined As The Coexistence of Daytime Urinary Continence, Clavien-Dindo ≥3 Complication-Free and Recurrence-Free Status, All Assessed At 1 Year.

Objective: To compare the outcomes of robotic radical nephrectomy (RRN) to those of laparoscopic radical nephrectomy (LRN) for large renal masses. Methods: This was a retrospective analysis of RRN and LRN cases performed for large (≥ cT2) renal masses from 2004 to 2017 and collected in the multi-institutional international database (ROSULA: RObotic SUrgery for LArge renal masses). Peri-operative, functional, and oncologic outcomes were compared between each approach.

Study Objective: To compare the effectiveness and safety of different techniques of hysteroscopic polypectomy. Design: Multicenter, prospective observational trial (Canadian Task Force classification II-2). Setting: Nineteen Italian gynecologic departments (university-affiliated or public hospitals). Patients: Consecutive patients suffering from endometrial polyps (EPs). Interventions: Hysteroscopic polypectomy, as performed through different techniques. Measurements and Main Results: Included in the study were 1404 patients (with 1825 EPs).

Objectives: The aim of this study was to evaluate the effectiveness and safety of adalimumab (ADA) in children with ulcerative colitis (UC) previously treated with infliximab (IFX). Methods: Retrospective study including children with UC from a national registry who received ADA therapy. The primary endpoint was the rate of corticosteroid-free remission at week 52. Secondary outcomes were the rate of sustained clinical remission, primary nonresponse, and loss of response at weeks 12, 30, and 52 and rate of mucosal healing and side effects at week 52.

Background: Data on the clinical course and outcomes of pediatric patients with cytomegalovirus (CMV) infection complicating acute severe ulcerative colitis (ASC) are very limited. The aim of our study was to compare outcomes of children with ASC who were CMV positive or CMV negative. Methods: This was a multicenter retrospective case-controlled study, from centers affiliated with the Pediatric Inflammatory Bowel Disease Porto Group of European Society of Pediatric Gastroenterology, Hepatology, and Nutrition.

BACKGROUND: Persistent human papillomavirus (HPV) infection constitutes the principal risk factor for the development of cervical intraepithelial neoplasia (CIN) and cervical cancer. For this reason, new drugs have been studied to support the host immune system against the HPV infection. The aim of this retrospective, case-control study was to detect the efficacy and safety of carboxymethyl ?-glucan (Colpofix®) gel as adjuvant therapy in HPV infection. METHODS: The medical records of patients attending the Colposcopy Service of four hospitals in Rome from 2011 to 2013 were collected.

BACKGROUND AND AIMS:
Immunosuppressive therapy for inflammatory bowel disease (IBD) in pediatric patients is thought to increase the risk of malignancy and lymphoproliferative disorders, including hemophagocytic lymphohistiocytosis (HLH). We compared unadjusted incidence rates of malignancy and HLH in pediatric patients with IBD exposed to infliximab (IFX) with patients not exposed to biologics and calculated standardized incidence ratios (SIRs).

In this study, we evaluated if surgical treatment and iterative operations could confer a survival advantage for patients with recurrent or repeated recurrences of thymoma.